• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Events

5th Joint Scientific Meeting HAT Platform – EANETT

3-4 October 2018

Kampala, Uganda

Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

The theme of the 5th Joint Scientific Meeting HAT Platform-EANETT is “Research and control activities challenges in keeping HAT below the elimination threshold beyond 2020”.

Sessions

NTD Elimination: The progress of HAT and new treatment perspectives

Date: Wednesday, 3 October 2018
Time: 9:45-11:20

Chairperson: Abdoulaye Diarra, Regional Office for Africa, World Health Organization
Deputy Chairman: Imna Malele, Vector & Vector-Borne Diseases Research Institute (VVBDI)
Rapporteurs: Barbara Nerima and Anne Nauteza

How to keep HAT below elimination threshold 2020: A situational overview: Keynote Address
José Ramon Franco, Department of Control of Neglected Tropical Diseases, WHO, Switzerland

DNDi’s NTD development programme in Africa
An update on fexinidazole
Nathalie Strub-Wourgaft, NTD Director, DNDi, Switzerland

HAT DNDi programme progress and evolution in the path to elimination
Antoine Tarral, Head of HAT Clinical Programmes, DNDi, Switzerland

 

Epidemiology, operational research & socio-economic issues for HAT elimination – Part 1

Time: 11:20-13:00

Chairperson: Abdoulaye Diarra, Regional Office for Africa, World Health Organization
Deputy Chairman: Imna Malele, Vector & Vector-Borne Diseases Research Institute (VVBDI)
Rapporteurs: Barbara Nerima and Anne Kazibwe

Impact of the Ebola outbreak on sleeping sickness in coastal Guinea: A retrospective analysis (2012-2017) from the Guinean national Human African Trypanosomiasis control program
Oumou Camara, HAT National Control Program, Ministry of Health, Guinea

Geographic distribution of human African trypanosomiasis cases in the Democratic Republic of Congo from 2011 to 2017: Spatial analysis of the HAT Atlas data
Shampa Chancy, HAT National Control Program, Ministry of Health, DRC

Quantifying transmission dynamics of HAT in peri-elimination era through mathematical modelling
Katherine Rock, Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, UK

Risk of resurgence of HAT in low-prevalence conflict areas: case of Kasai Occidental province in the DRC
Samuel Rashidi, HAT National Control Program, Ministry of Health, DRC

Sensing sleeping sickness: local symptom-making in South Sudan
Jennifer Palmer, Medical Anthropologist and Deputy Director, Health in Humanitarian Crises Centre, LSHTM, UK

Innovative tools and quality data to achieve the elimination of sleeping sickness
Alain Mpanya, HAT National Control Program, Ministry of Health, DRC

Human African Trypanosomiasis (HAT), epidemiological, diagnostic, therapeutic and evolutionary aspects in children and adolescents in the three care sites in Guinea
Ansoumane Kourouma, Key Laboratory of Environment and Health, Huazhong University of Science and Technology

An active search strategy for unconfirmed CATT positive suspects set up by a health zone team in the DRC
Matthieu Nkieri, Zone rurale de santé de Bagata

 

Epidemiology, operational research & socio-economic issues for HAT elimination – Part 2

Time: 14:00-15:15

Chairperson: Abdoulaye Diarra, Regional Office for Africa, World Health Organization
Deputy Chairman: Imna Malele, Vector & Vector-Borne Diseases Research Institute (VVBDI)
Rapporteurs: Anne Nauteza and Anne Kazibwe

Enhanced Screening and Diagnosis of gambiense Human African Trypanosomiasis in North-western Uganda – Moving Towards Elimination
Charles Wamboga, National Control Program, Ministry of Health, Uganda

HAT assimilated to witchcraft in endemic areas in the DRC: presentation of a clinical case
Helene Mahenzi, HAT Investigator, DNDi

Enhanced passive screening for HAT in Angola – progress towards elimination
Paulo Makana, Head of Department for Technical Management and Supervision. Institute for Combat and Control of Trypanosomiasis, Angola

Enhanced passive screening for HAT in a troubled transboundary focus in the Republic of Congo
Bienvenu Ossibi, Service des Maladies Infectieuses, CHU-Brazzaville, DRC

Enhanced passive screening for HAT in Kongo Central province of the DRC – progress towards elimination after three years
Simon Kayembe, HAT National Control Program, Ministry of Health, DRC

 

Research for new diagnostic and treatment options – Part 1

Time: 15:15-16:20

Chairperson: Sylvain Bieler, Senior Project Manager, FIND, Switzerland
Deputy Chairman: Augustin Kadima Ebeja, Coordinator, HAT Platform
Rapporteurs: Anne Nauteza and Anne Kazibwe

The immune trypanolysis test as a diagnostic tool for rational follow-up of serological suspects until detection of Trypanosoma brucei gambiense
Jeannette Bahota

Evaluation of the sensitivity of primers used for the PCR diagnosis of human African trypanosomiasis due to Trypanosoma brucei gambiense in guinea costal foci
Hamidou Ilboudou, Researcher at the “Centre International de Recherche-Développement sur l’Elevage en zone Subhumide”, Burkina Faso

Use of the immune trypanolysis test to detect T.b. gambiense-specific antibodies in sera from domestic animals in silent and hypoendemic sleeping sickness foci in the Democratic Republic of the Congo (Foci of Boko-Kivulu and Boma in Kongo Central Province)
Pati Pyana, Quality Specialist, DNDi, DRC

Surveillance model combining rapid testing and collection of filter papers in a network of sentinel sites in North Ecuador, DR Congo
Charles Kambo, CDI Bwamanda, DRC

Performance of diagnostic algorithms based on Rapid Diagnostic Tests to detect sleeping sickness
Jacquies Makabuza, National Sleeping Sickness Control Programme, DRC

 

Research for new diagnostic and treatment options – Part 2

Time: 16:30-18:00

Chairperson: Sylvain Bieler, Senior Project Manager, FIND, Switzerland
Deputy Chairman: Augustin Kadima Ebeja, Coordinator, HAT Platform
Rapporteurs: Anne Nauteza and Anne Kazibwe

Identification of Novel Stage Diagnostic Bio-markers in plasma of Trypanosoma brucei rhodesiense Sleeping Sickness Patients in Uganda
Charles Kato, Department of Bio molecular Resources and Bio laboratory Sciences, Makerere University, Uganda

Increasing the Toolbox for Trypanosomiasis Control: Exploring Efficacy of Metacyclic Antigens for Mammalian Vaccines
Serap Aksoy, Professor of Epidemiology, Department of Epidemiology of Microbial Diseases, Yale University, USA

Potential of Cerebrospinal fluid Interleukin-6 and Neopterin in discriminating between early and late stage Trypanosoma brucei rhodesiense sleeping sickness patients in Uganda
Ansiimwe Immaculate

Therapeutical approach in experimental trypanosomiasis by assessment of posaconazole
Romaric Nzoumbou, Laboratoire de Parasitologie, Université de Bordeaux, France

Evolution of the nutritional status of children included in the DNDiHATFEX006 study in the Democratic Republic of Congo, between the time of diagnosis and the end at 12-month follow-up
Digas Ngolo, Investigator Coordinator, DNDi

Some study on Sulphadimidine, Gentamicin, Oxytetracycline and their Combinations in Nubian Goats Experimentally Infected with Trypanosoma evansi
Fairouz Youssif, Central Veterinary Research Laboratory, Sudan

Description of an active hearth of disease of the sleep in the southern periphery of Kinshasa (DRC), by xénomonitoring
Philemon Mansinsa, National Sleeping Sickness Control Programme, DRC

 

Vector control & genomics/genetics for HAT elimination

Date: Thursday, 4 October 2018
Time
: 8:30-10:30

Chairperson: Grace Murilla
Deputy Chairman: Charles Kato, Department of Bio molecular Resources and Bio laboratory Sciences, Makerere University, Uganda
Rapporteurs: Anne Nauteza and Anne Kazibwe

Improving efficiency and quality in clinical trials in sub-Saharan Africa. Temporal genetic differentiation in Glossina pallidipes tsetse fly populations in Kenya
Winnie Okeyo, Yale School of Public Health, USA, Department of Biomedical Sciences and Technology, Maseno University, and Kenya Agricultural and Livestock Research Organization, Kenya

Spatio-temporal dynamics of African human Trypanosomiasis fly flies in the Nola-Bilolo focus, Central African Republic
Yvon Andjingbopou, University of Bangui, Central African Republic

Molecular Xenomonitoring of Trypanosome in tsetse for prioritizing vector control and HAT elimination in northern Tanzania
Imna Malele, Vector & Vector-Borne Diseases Research Institute (VVBDI)

NGU-2B: An Appropriate Trap for Control and Monitoring of Glossina morsitans morsitans in the Karamoja Drylands Agroecological Zone, Uganda
Patrick Abila, National Livestock Resources Research Institute (NaLIRRI), Uganda

Responses of Glossina pallidipes and

Glossina morsitans morsitans tsetse flies to analogues of δ-octalactone and selected blends
Benson Wachira, Department of Chemistry, Kenyatta University, Kenya

Assessment of the socio-economic and environmental impacts of the project for the creation of tsetse fly and trypanosomosis release zones four years after its closure
Percoma Lassane, The Pan African Tsetse and Trypanosomiasis Eradication Campaign (PATTEC), Burkina Faso

Putative protective association with Human African Trypanosomiasis in Democratic Republic of the Congo by SNPs in IL4 and INFG
Olivier Fataki, Institut National de Recherche Biomedicale, DRC

A spatial genetics approach to inform vector control of tsetse flies (Glossina fuscipes fuscipes) in Northern Uganda
Robert Opiro, Department of Biology, Faculty of Science, Gulu University, Uganda

More information:

Full programme

Other events

Loading...
8-12 May 2023

Lisbon, Portugal and online

ESPID 2023

13 April 2023, 2 PM London

London, United Kingdom

Ending the neglect of Chagas disease in the UK

11-12 April 2023

Barcelona, Spain and online

XVIII Jornadas sobre la enfermedad de Chagas

27-31 March 2023

Online

Global meeting on skin-related neglected tropical diseases

See all

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo